ClinicalTrials.gg
CompletedNCT02752035Updated Jul 14, 2026Results posted

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

A Phase 3 interventional study of gilteritinib and azacitidine in Acute Myeloid Leukemia (AML) and Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 111 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
13th of 31
183 · median 97
Started
2016
with 2 others
Phase 3
8 of 31
3 open now
Registered
7th of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 8 in phase 3, and was the 7th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This was a clinical study for adult participants who were recently diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some participants with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster.

For participants with AML who could not receive standard chemotherapy, azacitidine (also known as Vidaza®) was a current standard of care treatment option in the United States. This clinical study tested an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib worked by stopping the leukemia cells from making the FLT3 protein. This helped stop the leukemia cells from growing faster.

This study compared two different treatments. Participants were assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental medicine gilteritinib in combination with azacitidine. There was a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.

Read the detailed description

Participants considered an adult according to local regulation at the time of obtaining informed consent participated in the study.

Safety Cohort Prior to initiation of the randomized trial, 15 participants were enrolled to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the study population.

Randomized Trial Approximately 250 participants were randomized in a 2:1 ratio to receive ASP2215 plus azacitidine (Arm AC) or azacitidine only (Arm C). Participants entered the screening period up to 14 days prior to the start of treatment. Participants administered treatment over 28-day cycles.

Earlier protocol versions included a 1:1:1 randomization ratio to receive Arm A: ASP2215, Arm AC: ASP2215 + azacitidine or Arm C: azacitidine. Participants previously randomized to Arm A continued following treatment and assessments as outlined in the protocol.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Keywords

  • AML
  • ASP2215
  • Newly Diagnosed AML
  • gilteritinib
  • Acute Myeloid Leukemia (AML)
  • FLT3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is considered an adult according to local regulation at the time of obtaining .
  • Subject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.
  • Subject is positive for FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD] [D835/I836] mutation) (or for Korea only: ITD alone or ITD with concurrent TKD activating mutation) in bone marrow or whole blood as determined by central laboratory. Note: Only requirement of FLT3 mutation assessment by central laboratory is only applicable to the randomization portion of the study.
  • Subject is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:

    • Subject is ≥ 65 years of age and ineligible for intensive induction chemotherapy.
    • Subject is ≥ 18 to 64 years of age and has any of the following comorbidities: [Ex-US Only]: Congestive heart failure ( {NYHA} class ≤ 3) or (Ef) ≤ 50%; [US Only]: Severe cardiac disorder e.g. congestive heart failure (New York Heart Association [NYHA] class ≤ 3) requiring treatment, ejection fraction ≤ 50%, or chronic stable angina; [Ex-US Only]: Creatinine > 2 mg/dL (177 µmol/L), dialysis or prior renal transplant; [US Only]: \< 45 mL/min; performance status ≥ 2;
    • [Ex-US Only]: Known pulmonary disease with decreased diffusion capacity of lung for carbon monoxide (DLCO) and/or requiring oxygen ≤ 2 liters per minute; [US Only] Severe pulmonary disorder (e.g., diffusion capacity of lung for carbon monoxide [DLCO] ≤ 65% or [FEV1] ≤ 65%); Prior or current that does not require concurrent treatment; Subject has received a cumulative anthracycline dose above 400 mg/m2 of doxorubicin (or cumulative maximum dose of another anthracycline). Any other comorbidity incompatible with intensive chemotherapy must be reviewed and approved by the Medical Monitor during screening and before randomization.
  • Subject must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum and ALT ≤ 3.0 x Institutional (ULN)
    • Serum total ≤ 1.5 x Institutional ULN
    • Serum potassium ≥ Institutional lower limit of normal (LLN)
    • Serum magnesium ≥ Institutional LLN Repletion of potassium and magnesium levels during the screening period is allowed.
  • Subject is suitable for oral administration of study drug.
  • Female subject is eligible to participate if female subject is not pregnant and at least one of the following conditions applies:

    • Not a woman of (WOCBP); OR
    • WOCBP agrees to follow the guidance starting at screening and continue throughout the study period, and for at least 180 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
  • Male subject with female partners of childbearing potential must agree to use contraception as detailed in Contraception Requirements, starting at screening and continue throughout the study period, and for 120 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
  • Subject agrees not to participate in another interventional study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject was diagnosed as acute promyelocytic leukemia (APL).
  • Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Subject has received previous therapy for AML, with the exception of the following:

    • Emergency leukapheresis
    • Hydroxyurea
    • Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
    • Growth factor or cytokine support
  • Subject has clinically active central nervous system leukemia.
  • Subject has been diagnosed with another that requires concurrent treatment (with the exception of hormone therapy limited to those therapies that prevent recurrence and/or spread of cancer) or hepatic malignancy regardless of need for treatment.
  • Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 /P-glycoprotein (P-gp).
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject has congestive heart failure classified as Class IV.
  • Subject with mean Fridericia- interval (QTcF) > 480 ms at screening based on central reading.
  • Subject with a history of Long QT Syndrome at screening.
  • [Ex-US Only]: Subject has known pulmonary function tests with diffusion capacity of lung for carbon monoxide (DLCO) ≤ 50%, (FEV1) ≤ 60%, dyspnea at rest or requiring oxygen or any pleural neoplasm (Transient use of supplemental oxygen is allowed.)
  • Subject has active or C or other active hepatic disorder.

    • Subjects with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B DNA are not eligible.
    • Subjects with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if hepatitis B DNA is undetectable.
    • Subjects with antibodies to virus will be eligible if hepatitis C RNA is undetectable
  • Subject has any condition which makes the subject unsuitable for study participation, including any of azacitidine.
  • Subject has a known or suspected to ASP2215, azacitidine or any components of the formulations used.
  • [US Only]: Subject is ≥ 65 to 74 years of age, suitable for and willing to receive intensive induction chemotherapy.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    Safety Cohort: Gilteritinib + Azacitidine (AZA)

    Participants received 80 mg (2 tablets of 40 mg) of gilteritinib orally once daily for continuous 28-day cycles and 75 mg/m\^2 of AZA daily via subcutaneous injection or intravenous infusion for 7 days of each 28-day treatment cycle. Depending on the safety cohort data ,the decision to initiate the randomized trial at the targeted dose was made. After the end of treatment period, participants were followed up for 30- day follow up period. Participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment, EQ-5D-5L, remission status and survival (cause of death and date of death). Participants in long-term follow-up who were no longer receiving treatment were followed every 3 months for survival until the implementation of the final protocol version 13.0, at which time they were discontinued from the study, as further survival data were no longer needed.

    Drug: gilteritinib · Drug: azacitidine

  • Experimental
    Randomized Cohort: Gilteritinib + AZA

    Participants received 120 mg(3 tablets of 40 mg)of gilteritinib orally once daily for continuous 28-day cycles in combination with 75mg/m\^2 of AZA daily via subcutaneous injection or IV infusion for 7days of each 28-day treatment cycle until the participant no longer received clinical benefit from therapy in the opinion of the investigator,unacceptable toxicity occurred,or the participant met another treatment discontinuation criterion.After the end of treatment period,participants were followed up for 30-day follow up period.Participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment,EQ-5D-5L,remission status and survival (cause and date of death).Participants in long-term follow-up who were no longer receiving treatment were followed every 3months for survival until the implementation of the final protocol version 13.0, at which time they were discontinued from the study,as further survival data were no longer needed.

    Drug: gilteritinib

  • Experimental
    Randomized Cohort: AZA

    Participants received 75 mg/m\^2 of AZA daily via subcutaneous injection or intravenous infusion for 7 days of each 28-day treatment cycle until the participant no longer received clinical benefit from therapy in the opinion of the investigator, unacceptable toxicity occurred or the participant met another treatment discontinuation criterion. After the end of treatment period, participants were followed up for 30- day follow up period. Participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment, EQ-5D-5L, remission status and survival (cause of death and date of death). Participants in long-term follow-up who were no longer receiving treatment were followed every 3 months for survival until the implementation of the final protocol version 13.0, at which time they were discontinued from the study, as further survival data were no longer needed.

    Drug: gilteritinib · Drug: azacitidine

  • Active comparator
    Randomized Cohort: Gilteritinib

    Participants received 120 mg (3 tablets of 40 mg) of gilteritinib orally once daily for continuous 28-day cycles until the participant no longer received clinical benefit from therapy in the opinion of the investigator, unacceptable toxicity occurred or the participant met another treatment discontinuation criterion. However, randomization to this arm was removed in protocol version 7.0. Participants previously randomized to this arm continued following treatment and assessments as outlined in the protocol.

    Drug: azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. Kaplan-Meier (KM) estimates was used for analysis.

    Time frame: From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)

Secondary outcomes

  1. Event-free Survival (EFS)

    EFS: time from the date of randomization until the date of documented relapse from Complete Remission (CR), treatment failure(failing to achieve CR within 6 cycles of treatment) or death from any cause, whichever occurred first. CR: bone marrow(BM) regenerating normal hematopoietic cells, morphologically leukemia-free state, absolute neutrophil count (ANC) ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being red blood cell (RBC) and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Relapse: reappearance of leukemic blasts \>2% in the peripheral blood/≥ 5% myeloblasts in the BM unattributable to any other cause/new/reappearance of extramedullary leukemia.

    Time frame: From the date of randomization until the date of documented relapse from CR, treatment failure or death from any cause, whichever occurred first (up to 39.7 months)

  2. Percentage of Participants With Best Response

    Best response for a participant was defined as the best measured response (in the order of CR, CR with Incomplete Platelet Recovery (CRp), CR with Incomplete Hematologic Recovery (CRi), and treatment failure) from all post-baseline visits. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required.

    Time frame: From the date of randomization until the date of death from any cause (up to 57 months)

  3. Completed Remission (CR) Rate

    CR rate: number of participants who achieved the best response of CR divided by the number of participants in the analysis population. Participants with unknown or missing response, or who provided no information on response at the end of treatment were included in the denominator when calculating rates. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent(1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods.

    Time frame: From the date of randomization until the date of death from any cause (approximately 49.7 months)

  4. CRc Rate

    CRc rate was defined as participants with best response of (CR + CRp + CRi) divided by the number of participants in the analysis population. Participants were classified as: CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. Percentage of participants with CRc was reported.

    Time frame: From the date of randomization until the date of death from any cause (approximately 54.5 months)

  5. Complete Remission With Partial Hematologic Recovery (CRh)

    CRh was defined as the response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Percentage of participants with CRh was reported.

    Time frame: From the date of randomization until the date of death from any cause (up to 49.7 months)

  6. CR/CRh Rate

    CR/CRh rate: number of participants who achieved CR or CRh divided by the number of participants in the analysis population. CR/CRh: CR/CRh if it fulfilled criteria for CR or CRh at the visit. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRh: response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. Percentage of participants with CR/CRh was reported.

    Time frame: From the date of randomization until the date of death from any cause (up to 49.7 months)

  7. Percentage of Participants With Transfusion Conversion Rate

    Transfusion conversion rate was defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period.

    Time frame: From baseline up to 57 months

  8. Percentage of Participants With Transfusion Maintenance Rate

    Transfusion maintenance rate was defined as the number of participants who were transfusion independent at baseline period and remained transfusion independent post-baseline period divided by the total number of participants who were transfusion independent at baseline period.

    Time frame: From baseline up to 57 months

  9. Leukemia-free Survival (LFS)

    LFS: time from the date of first CRc (CR + CRp + CRi) until the date of documented relapse (excluding relapse from PR) or death for participants who achieved CRc. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. CRc: fulfilled criteria for CR, CRp or CRi. Based on KM estimates.

    Time frame: From first day of achieving first CRc to the first day of confirmed relapse/death (up to 54.5 months)

  10. Duration of Remission

    Duration of remission included CRc, CR, CRh, CR/CRh, and response duration \[CRc + PR\]. Duration of CRc, CR, CRh: the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR, and CRh, respectively. CR/CRh: fulfilled criteria for CR or CRh at the visit. CRh: marrow blasts \<5%, ANC ≥0.5×10\^9/L, platelets ≥50×10\^9/L, not meeting CR criteria. PR: If marrow myeloblasts between \<5% and 25% and ≤2% or missing peripheral blood blast and a decrease from baseline of at least 50% in the marrow myeloblasts and no evidence of extramedullary leukemia, the response was classified as PR. If marrow myeloblasts \<5% and ≤2% or missing peripheral blood blast and no evidence of extramedullary leukemia, the response was classified as PR even with Auer rods.

    Time frame: From first day of achieving first response to the first day of confirmed relapse/death (up to 56.4 months)

  11. Change From Baseline in Brief Fatigue Inventory (BFI)

    The BFI was a tool to assess fatigue severity and impact on daily function in cancer participants over 24 hours. It included 9 items. A global fatigue score was computed by averaging the scores of the 9 items measured on the numeric rating scale. Scores were calculated if ≥5 of 9 items were answered. A higher score indicates a higher degree of fatigue. The first 3 rate fatigue from 0 (no fatigue) to 10 (worst imaginable), with higher scores indicating worse outcomes. The remaining 6 assess how fatigue interferes with daily activities from 0 (no interference) to 10 (completely interferes). A global fatigue score (0-10) was the average of all items, with higher scores indicating worse fatigue. Overall BFI score is reported.

    Time frame: From baseline to 31 months

  12. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug until 30 days from the last study treatment

    Time frame: From first dose up to end of study duration (101 months)

  13. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores

    ECOG performance scores at each assessment time were be provided by treatment group. Negative change scores indicated an improvement and positive scores indicate a decline in performance. The grades were defined as follows: 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

    Time frame: From baseline to end of treatment (up to 57 months)

07

Results

Posted Sep 12, 2025
Limitations and caveats
Protocol versions 6.0 and earlier included a 1:1:1 randomization ratio to receive Gilteritinib + AZA, AZA-only and Gilteritinib-only. Randomization to arm Gilteritinib-only was removed in protocol version 7.0. Participants previously randomized to Gilteritinib-only arm continued following treatment and assessments as outlined in the protocol.

Participant flow

Participants with newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) not eligible for intensive induction were enrolled.

Safety Cohort: Approximately 5 Years
Participant flow — Safety Cohort: Approximately 5 Years
MilestoneSafety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Started15000
Completed0000
Not completed15000
Withdrew: Miscellaneous2000
Withdrew: Disease relapse5000
Withdrew: Withdrawal by subject1000
Withdrew: Lack of efficacy1000
Withdrew: Death5000
Withdrew: Adverse event1000
Randomization: Approximately 3 Years
Participant flow — Randomization: Approximately 3 Years
MilestoneSafety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Started0895722
Completed0000
Not completed0895722
Withdrew: Miscellaneous0741
Withdrew: Disease relapse022166
Withdrew: Physician decision0311
Withdrew: Withdrawal by subject01474
Withdrew: Lack of efficacy04140
Withdrew: Death025134
Withdrew: Adverse event01426
Long-term Follow-up: up to 3 Years
Participant flow — Long-term Follow-up: up to 3 Years
MilestoneSafety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Started5333410
Completed0000
Not completed5333410
Withdrew: Withdrawal by subject0330
Withdrew: Lost to follow-up0110
Withdrew: Death5263010
Withdrew: Miscellaneous0300

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. Kaplan-Meier (KM) estimates was used for analysis.

Time frame:
From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)
Reported as:
Median · months
Overall Survival (OS)
monthsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Overall Survival (OS)9.82 (8.11 to 13.17)9.23 (4.34 to 12.55)5.24 (2.46 to 15.18)
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.523 · Hazard ratio (hr): 0.870 · 95% CI 0.570 to 1.329Based on Cox proportional hazards model.
SecondaryEvent-free Survival (EFS)

EFS: time from the date of randomization until the date of documented relapse from Complete Remission (CR), treatment failure(failing to achieve CR within 6 cycles of treatment) or death from any cause, whichever occurred first. CR: bone marrow(BM) regenerating normal hematopoietic cells, morphologically leukemia-free state, absolute neutrophil count (ANC) ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being red blood cell (RBC) and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Relapse: reappearance of leukemic blasts \>2% in the peripheral blood/≥ 5% myeloblasts in the BM unattributable to any other cause/new/reappearance of extramedullary leukemia.

Time frame:
From the date of randomization until the date of documented relapse from CR, treatment failure or death from any cause, whichever occurred first (up to 39.7 months)
Reported as:
Median · months
Event-free Survival (EFS)
monthsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Event-free Survival (EFS)0.03 (NA to NA)0.03 (NA to NA)0.03 (0.03 to 2.46)
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.787 · Hazard ratio (hr): 0.940 · 95% CI 0.635 to 1.393Based on Cox proportional hazards model.
SecondaryPercentage of Participants With Best Response

Best response for a participant was defined as the best measured response (in the order of CR, CR with Incomplete Platelet Recovery (CRp), CR with Incomplete Hematologic Recovery (CRi), and treatment failure) from all post-baseline visits. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required.

Time frame:
From the date of randomization until the date of death from any cause (up to 57 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Response
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
CR25.817.59.1
CRp6.7018.2
CRi29.210.527.3
SecondaryCompleted Remission (CR) Rate

CR rate: number of participants who achieved the best response of CR divided by the number of participants in the analysis population. Participants with unknown or missing response, or who provided no information on response at the end of treatment were included in the denominator when calculating rates. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent(1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods.

Time frame:
From the date of randomization until the date of death from any cause (approximately 49.7 months)
Reported as:
Number · percentage of participants
Completed Remission (CR) Rate
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Completed Remission (CR) Rate25.817.59.1
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Cochran-Mantel-Haenszel · p = 0.249 (Based on stratified Cochran-Mantel-Haenszel test. Stratification factor was age group per interactive response technology.) · Treatment difference: 8.2 · 95% CI -6.5 to 23.0
SecondaryCRc Rate

CRc rate was defined as participants with best response of (CR + CRp + CRi) divided by the number of participants in the analysis population. Participants were classified as: CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. Percentage of participants with CRc was reported.

Time frame:
From the date of randomization until the date of death from any cause (approximately 54.5 months)
Reported as:
Number · percentage of participants
CRc Rate
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
CRc Rate61.828.154.5
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Cochran-Mantel-Haenszel · p = <0.001 (Based on stratified Cochran-Mantel-Haenszel test. Stratification factor was age group per interactive response technology.) · Treatment difference: 33.3 · 95% CI 16.6 to 50.0
SecondaryComplete Remission With Partial Hematologic Recovery (CRh)

CRh was defined as the response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. Percentage of participants with CRh was reported.

Time frame:
From the date of randomization until the date of death from any cause (up to 49.7 months)
Reported as:
Number · percentage of participants
Complete Remission With Partial Hematologic Recovery (CRh)
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Complete Remission With Partial Hematologic Recovery (CRh)10.11.822.7
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Cochran-Mantel-Haenszel · p = 0.049 (Based on stratified Cochran-Mantel-Haenszel test. Stratification factor was age group per interactive response technology.) · Treatment difference: 8.5 · 95% CI -0.1 to 17.1
SecondaryCR/CRh Rate

CR/CRh rate: number of participants who achieved CR or CRh divided by the number of participants in the analysis population. CR/CRh: CR/CRh if it fulfilled criteria for CR or CRh at the visit. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRh: response at a post baseline visit as CRh having bone marrow myeloblast count \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood must be ≤ 2% or missing. Percentage of participants with CR/CRh was reported.

Time frame:
From the date of randomization until the date of death from any cause (up to 49.7 months)
Reported as:
Number · percentage of participants
CR/CRh Rate
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
CR/CRh Rate36.019.331.8
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Cochran-Mantel-Haenszel · p = 0.032 (Based on stratified Cochran-Mantel-Haenszel test. Stratification factor was age group per interactive response technology.) · Treatment difference: 16.7 · 95% CI 1.1 to 32.4
SecondaryPercentage of Participants With Transfusion Conversion Rate

Transfusion conversion rate was defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period.

Time frame:
From baseline up to 57 months
Reported as:
Number · percentage of participants
Percentage of Participants With Transfusion Conversion Rate
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Percentage of Participants With Transfusion Conversion Rate35.6 (24.7 to 47.7)44.7 (28.6 to 61.7)61.1 (35.7 to 82.7)
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Cochran-Mantel-Haenszel · p = 0.340 (Based on stratified Cochran-Mantel-Haenszel test. Stratification factor was age group per interactive response technology.) · Treatment difference: -9 · 95% CI -29.8 to 11.0
SecondaryPercentage of Participants With Transfusion Maintenance Rate

Transfusion maintenance rate was defined as the number of participants who were transfusion independent at baseline period and remained transfusion independent post-baseline period divided by the total number of participants who were transfusion independent at baseline period.

Time frame:
From baseline up to 57 months
Reported as:
Number · percentage of participants
Percentage of Participants With Transfusion Maintenance Rate
percentage of participantsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Percentage of Participants With Transfusion Maintenance Rate100.0 (29.2 to 100.0)50.0 (1.3 to 98.7)50.0 (1.3 to 98.7)
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Cochran-Mantel-Haenszel · p = 0.221 (Based on stratified Cochran-Mantel-Haenszel test. Stratification factor was age group per interactive response technology.) · Treatment difference: 50 · 95% CI -61.0 to 100.0
SecondaryLeukemia-free Survival (LFS)

LFS: time from the date of first CRc (CR + CRp + CRi) until the date of documented relapse (excluding relapse from PR) or death for participants who achieved CRc. CR: BM regenerating normal hematopoietic cells, morphologically leukemia-free state, ANC ≥1 × 10\^9/L, platelet count ≥100 × 10\^9/L, normal marrow differential with \<5% myeloblast counts, missing/≤2% peripheral blood blast counts and being RBC and platelet transfusion independent (1 week without RBC and platelet transfusion prior to the disease assessment). No evidence of extramedullary leukemia and Auer rods. CRp: achieved CR except incomplete platelet recovery (\< 100 × 10\^9/L). CRi: achieved CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence not required. CRc: fulfilled criteria for CR, CRp or CRi. Based on KM estimates.

Time frame:
From first day of achieving first CRc to the first day of confirmed relapse/death (up to 54.5 months)
Reported as:
Median · months
Leukemia-free Survival (LFS)
monthsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Leukemia-free Survival (LFS)7.16 (6.01 to 12.52)8.08 (2.46 to 14.09)3.20 (0.89 to 6.87)
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.592 · Hazard ratio (hr): 0.844 · 95% CI 0.451 to 1.580Based on Cox proportional hazards model adjusting age group per IRT.
SecondaryDuration of Remission

Duration of remission included CRc, CR, CRh, CR/CRh, and response duration \[CRc + PR\]. Duration of CRc, CR, CRh: the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR, and CRh, respectively. CR/CRh: fulfilled criteria for CR or CRh at the visit. CRh: marrow blasts \<5%, ANC ≥0.5×10\^9/L, platelets ≥50×10\^9/L, not meeting CR criteria. PR: If marrow myeloblasts between \<5% and 25% and ≤2% or missing peripheral blood blast and a decrease from baseline of at least 50% in the marrow myeloblasts and no evidence of extramedullary leukemia, the response was classified as PR. If marrow myeloblasts \<5% and ≤2% or missing peripheral blood blast and no evidence of extramedullary leukemia, the response was classified as PR even with Auer rods.

Time frame:
From first day of achieving first response to the first day of confirmed relapse/death (up to 56.4 months)
Reported as:
Median · months
Duration of Remission
monthsRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Duration of CR/CRh19.94 (6.93 to NA)8.08 (0.95 to 8.57)2.83 (1.87 to 5.95)
Duration of CR25.10 (7.39 to NA)8.25 (0.95 to NA)NA (NA to NA)
Duration of CRc12.52 (6.77 to NA)8.25 (2.10 to 14.09)3.65 (0.89 to 7.39)
Duration of CRh6.77 (1.35 to 6.93)8.08 (NA to NA)2.83 (1.87 to 5.95)
Duration of response7.92 (3.98 to 18.40)7.62 (0.95 to 9.23)3.65 (0.95 to 6.87)
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.300 · Hazard ratio (hr): 0.573 · 95% CI 0.198 to 1.658Based on Cox proportional hazards model adjusting age group per IRT.
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.171 · Hazard ratio (hr): 0.411 · 95% CI 0.113 to 1.504Based on Cox proportional hazards model adjusting age group per IRT.
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.383 · Hazard ratio (hr): 0.691 · 95% CI 0.295 to 1.620Based on Cox proportional hazards model adjusting age group per IRT.
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.998 · Hazard ratio (hr): 999Based on Cox proportional hazards model adjusting age group per IRT.
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · Log Rank · p = 0.174 · Hazard ratio (hr): 0.628 · 95% CI 0.321 to 1.229Based on Cox proportional hazards model adjusting age group per IRT.
SecondaryChange From Baseline in Brief Fatigue Inventory (BFI)

The BFI was a tool to assess fatigue severity and impact on daily function in cancer participants over 24 hours. It included 9 items. A global fatigue score was computed by averaging the scores of the 9 items measured on the numeric rating scale. Scores were calculated if ≥5 of 9 items were answered. A higher score indicates a higher degree of fatigue. The first 3 rate fatigue from 0 (no fatigue) to 10 (worst imaginable), with higher scores indicating worse outcomes. The remaining 6 assess how fatigue interferes with daily activities from 0 (no interference) to 10 (completely interferes). A global fatigue score (0-10) was the average of all items, with higher scores indicating worse fatigue. Overall BFI score is reported.

Time frame:
From baseline to 31 months
Reported as:
Mean · Scores on scale
Change From Baseline in Brief Fatigue Inventory (BFI)
Scores on scaleRandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Change From Baseline in Brief Fatigue Inventory (BFI)0.77 ± 3.980.87 ± 2.921.37 ± 3.49
Statistical analysis
  • Randomized Cohort: Gilteritinib + AZA vs Randomized Cohort: AZA · ANCOVA · p = 0.560 · Least square mean difference: 0.5 · 95% CI -1.1 to 2.0Least square mean difference and P-value were calculated using AZA as reference.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE was defined as an adverse event observed after starting administration of the study drug until 30 days from the last study treatment

Time frame:
From first dose up to end of study duration (101 months)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsSafety Cohort: Gilteritinib + AZARandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Number of Participants With Treatment Emergent Adverse Events (TEAEs)15885222
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores

ECOG performance scores at each assessment time were be provided by treatment group. Negative change scores indicated an improvement and positive scores indicate a decline in performance. The grades were defined as follows: 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

Time frame:
From baseline to end of treatment (up to 57 months)
Reported as:
Number · participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Scores
participantsSafety Cohort: Gilteritinib + AZARandomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Baseline: Grade 011593
Baseline: Grade 1434266
Baseline: Grade 2428149
Baseline: Grade 361053
Baseline: Grade 40101
Baseline: Grade 50000
End of Treatment (EOT): Grade 01482
EOT: Grade 1112154
EOT: Grade 2212113
EOT: Grade 31711
EOT: Grade 41611
EOT: Grade 50000

Adverse events

Collected over All-cause mortality (ACM): From randomization up to end of study duration (101 months) AEs: From first dose up to end of study duration (101 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Cohort: Gilteritinib + Azacitidine (AZA)14/15 (93.3%)14/15 (93.3%)15/15 (100%)
Randomized Cohort: Gilteritinib + AZA70/89 (78.7%)81/88 (92%)87/88 (98.9%)
Randomized Cohort: AZA49/57 (86%)34/54 (63%)46/54 (85.2%)
Randomized Cohort: Gilteritinib22/22 (100%)20/22 (90.9%)22/22 (100%)
Most frequent serious events
Showing 10 of 196
Most frequent serious events
EventSafety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
Febrile neutropeniaBlood and lymphatic system disorders8/1528/8810/544/22
PneumoniaInfections and infestations4/1519/888/545/22
PyrexiaGeneral disorders3/1512/881/545/22
Septic shockInfections and infestations2/156/881/545/22
AnaemiaBlood and lymphatic system disorders3/154/880/542/22
Atrial fibrillationCardiac disorders3/157/880/541/22
SepsisInfections and infestations2/159/885/544/22
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/156/880/543/22
Acute kidney injuryRenal and urinary disorders2/154/881/543/22
NeutropeniaBlood and lymphatic system disorders2/150/881/540/22
Most frequent other events
Showing 10 of 170
Most frequent other events
EventSafety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: Gilteritinib
AnaemiaBlood and lymphatic system disorders8/1528/8818/546/22
NeutropeniaBlood and lymphatic system disorders7/1528/8816/543/22
DiarrhoeaGastrointestinal disorders7/1530/8810/549/22
PyrexiaGeneral disorders2/1537/8817/545/22
ThrombocytopeniaBlood and lymphatic system disorders6/1529/8811/544/22
NauseaGastrointestinal disorders6/1527/8813/543/22
FatigueGeneral disorders6/158/885/540/22
Alanine aminotransferase increasedInvestigations6/1515/885/543/22
Aspartate aminotransferase increasedInvestigations6/1519/883/544/22
ConstipationGastrointestinal disorders5/1535/8813/545/22

Baseline characteristics

The Full Analysis Set (FAS) was defined as the intention to treat set, which consisted of participants who were randomized and were used for efficacy analyses.

Age, Continuous
Age, Continuous(Years)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
Mean75.3 ± 5.677.1 ± 5.776.9 ± 5.278.5 ± 4.277.1 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
Female840271085
Male749301298
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
Hispanic or Latino02417
Not Hispanic or Latino14754618153
Unknown or Not Reported1127323
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
Race — White1153339106
Race — Asian325151053
Race — Unknown1118222
Race — Other00112
Age group per Interactive Response Technology (IRT)
Age group per Interactive Response Technology (IRT)(Participants)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
< 75 years62715452
>= 75 years9624218131
FMS-like tyrosine kinase 3 (FLT3) mutation type
FMS-like tyrosine kinase 3 (FLT3) mutation type(Participants)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
Internal Tandem Duplication (ITD) Alone10704617143
Tyrosine Kinase Domain (TKD) (D835/I836) Alone3169230
ITD with TKD (D835/I836)13239
Others (unknown/missing/negative)10001
Cytogenetic risk status
Cytogenetic risk status(Participants)Safety Cohort: Gilteritinib + Azacitidine (AZA)Randomized Cohort: Gilteritinib + AZARandomized Cohort: AZARandomized Cohort: GilteritinibTotal
Favorable02002
Intermediate11634017131
Unfavorable196016
Others (unknown, missing)31511534
08

Study locations

111 sites
  • UCLA David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
  • Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611-5975, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • St. Louis University Cancer Center - Hematology/Oncology
    St Louis, Missouri 63110, United States
  • Hackensack University Medical Center - John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Hematology-Oncology Associates of Northern NJ
    Morristown, New Jersey 07962, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Weill Cornell Medical College-New York Presbyterian Hospital
    New York, New York 10021, United States
  • GHS Cancer Institute
    Greenville, South Carolina 26615, United States
  • LDS Hospital
    Salt Lake City, Utah 84143, United States
  • Site AU61004
    Liverpool, New South Wales 2170, Australia
  • Site AU61008
    Adelaide, South Australia SA 5000, Australia
  • Site AU61007
    Geelong, Victoria 3220, Australia
  • Site BE32007
    Brussels, Brussels Capital 1090, Belgium
  • Site BE32003
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
  • Site BE32006
    Ghent, 9000, Belgium
  • Site CA15009
    Edmonton, Alberta T6G 2B7, Canada
  • Site CA15011
    Toronto, Ontario M4N 3M5, Canada
  • Site CA15002
    Toronto, Ontario M5G 2M9, Canada
  • Site CA15006
    Montreal, Quebec H4A 3J1, Canada
  • Site FR33003
    Nîmes, Gard 30029, France
  • Site FR33002
    Pessac, Gironde 33604, France
  • Site FR33015
    Rouen, Haute-Normandie 76038, France
  • Site FR33019
    Montpellier, Herault 34295, France
  • Site FR33018
    Rennes, Ille-et-Vilaine 35033, France
  • Site FR33001
    Nantes, Loire-Atlantique 44093, France
  • Site FR33023
    Valenciennes, Nord 59322, France
  • Site FR33013
    Pierre-Bénite, Rhone 69310, France
  • Site FR33017
    Le Mans, Sarthe 72037, France
  • Site FR33012
    Poitiers, Vienne 86000, France
  • Site FR33009
    Angers, 49033, France
  • Site FR33020
    Bayonne, France
  • Site FR33004
    Lille, 59020, France
  • Site FR33006
    Lille, 59037, France
  • Site DE49002
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Site DE49007
    München, Bavaria 81737, Germany
  • Site DE49005
    Frankfurt am Main, Hesse 60590, Germany
  • Site DE49012
    Braunschweig, Lower Saxony 38118, Germany
  • Site DE49004
    Hanover, Lower Saxony 30625, Germany
  • Site DE49015
    Rostock, Mecklenburg-Vorpommern 18057, Germany
  • Site DE49009
    Halle, Saxony-Anhalt 06120, Germany
  • Site DE49003
    Berlin, 13353, Germany
  • Site DE49011
    Stuttgart, 70376, Germany
  • Site IT39009
    Ancona, 60126, Italy
  • Site IT39015
    Bologna, 40138, Italy
  • Site IT39012
    Florence, Italy
  • Site IT39004
    Milan, 20162, Italy
  • Site IT39007
    Monza, Italy
  • Site IT39001
    Naples, 80131, Italy
  • Site IT39014
    Novara, Italy
  • Site IT39006
    Palermo, 90146, Italy
  • Site IT39005
    Pavia, Italy
  • Site IT39011
    San Giovanni Rotondo, 71013, Italy
  • Site JP81018
    Anjo, Aichi-ken, Japan
  • Site JP81007
    Nagoya, Aichi-ken, Japan
  • Site JP81027
    Matsuyama, Ehime, Japan
  • Site JP81021
    Fukuyama, Hiroshima, Japan
  • Site JP81031
    Sapporo, Hokkaido, Japan
  • Site JP81033
    Sapporo, Hokkaido, Japan
  • Site JP81015
    Kobe, Hyōgo, Japan
  • Site JP81034
    Hitachi, Ibaraki, Japan
  • Site JP81023
    Kanazawa, Ishikawa-ken, Japan
  • Site JP81001
    Isehara, Kanagawa, Japan
  • Site JP81032
    Yokohama, Kanagawa, Japan
  • Site JP81012
    Sendai, Miyagi, Japan
  • Site JP81011
    Kurashiki, Okayama-ken, Japan
  • Site JP81029
    Shibuya-ku, Tokyo, Japan
  • Site JP81014
    Shinagawa-ku, Tokyo, Japan
  • Site JP81035
    Chiba, Japan
  • Site JP81008
    Fukuoka, Japan
  • Site JP81024
    Gifu, Japan
  • Site JP81005
    Kumamoto, Japan
  • Site JP81016
    Kyoto, Japan
  • Site JP81004
    Nagasaki, Japan
  • Site JP81017
    Nagasaki, Japan
  • Site JP81030
    Osaka, Japan
  • Site JP81036
    Osaka, Japan
  • Site JP81026
    Tokushima, Japan
  • Site JP81019
    Toyama, Japan
  • Site PL48003
    Lublin, Lublin Voivodeship 20-081, Poland
  • Site PL48004
    Warsaw, Masovian Voivodeship 02-776, Poland
  • Site PL48002
    Opole, Opole Voivodeship 45-061, Poland
  • Site PL48001
    Olsztyn, Warmian-Masurian Voivodeship 10-228, Poland
  • Site KR82003
    Namdong, Incheon Gwang'yeogsiv 405 760, South Korea
  • Site KR82013
    Seoul, Seoul Teugbyeolsi 05505, South Korea
  • Site KR82006
    Seoul, Seoul Teugbyeolsi 110-744, South Korea
  • Site KR82002
    Seoul, Seoul Teugbyeolsi 137-701, South Korea
  • Site KR82001
    Ulsan, Ulsan Gwang'yeogsi 682-714, South Korea
  • Site KR82014
    Busan, 49241, South Korea
  • Site KR82010
    Hwasun-gun, South Korea
  • Site KR82015
    Seongnam-si, South Korea
  • Site KR82012
    Seoul, 156-707, South Korea
  • Site ES34007
    Palma de Mallorca, Balearic Islands 07010, Spain
  • Site ES34003
    Oviedo, Principality of Asturias 33011, Spain
  • Site ES34008
    Barcelona, 08003, Spain
  • Site ES34004
    Barcelona, 08035, Spain
  • Site ES34010
    Barcelona, 08036, Spain
  • Site ES34009
    Barcelona, 8041, Spain

Showing the first 100 of 111 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. PubMed 35917453 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Mar 2023, 79 months.

Results were first posted in Sep 2025, 2 years 6 months after primary completion. A results delay was requested in Mar 2024.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 79 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2016
First posted
Apr 26, 2016
StartActual
Aug 1, 2016
Primary completionActual
Mar 10, 2023
CompletionActual
Dec 18, 2024
Results delay requested
Mar 7, 2024
Results first posted
Sep 12, 2025
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02752035
Responsible party
Sponsor
First posted
Apr 26, 2016
Start date
Aug 1, 2016
Primary completion
Mar 10, 2023
Completion
Dec 18, 2024
Results posted
Sep 12, 2025
Last update
Jul 14, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gilteritinib · Azacitidine

Start the discussion